Letter to the editor
Commentary on Yücel DE et al. Downgrading recommendation level of prazosin for treating trauma-related nightmares: Should decision be based on a single study?

https://doi.org/10.1016/j.smrv.2020.101285Get rights and content

Section snippets

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81900087, 81530002, 81800093).

References (32)

  • T.D. Hurwitz et al.

    Polysomnographic sleep is not clinically impaired in Vietnam combat veterans with chronic posttraumatic stress disorder

    Biol Psychiatr

    (1998)
  • V. Mysliwiec et al.

    Trauma associated sleep disorder: a parasomnia induced by trauma

    Sleep Med Rev

    (2018)
  • American Academy of Sleep Medicine

    International classification of sleep disorders

    (2014)
  • R.N. Aurora et al.

    Best practice guide for the treatment of nightmare disorder in adults

    J Clin Sleep Med

    (2010)
  • G. Loeffler et al.

    Prescribing trends in US active duty service members with posttraumatic stress disorder: a population-based study from 2007-2013

    J Clin Psychiatr

    (2018)
  • M.A. Raskind et al.

    Trial of prazosin for post-traumatic stress disorder in military veterans

    N Engl J Med

    (2018)
  • Cited by (6)

    • Efficacy and acceptability of psychotherapeutic and pharmacological interventions for trauma-related nightmares: A systematic review and network meta-analysis

      2022, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      In 2010, the American Academy of Sleep Medicine (AASM) recommended one cognitive behavioral intervention, image rehearsal therapy (IRT) and one pharmacological agent, prazosin, as level A treatments for TRN (Aurora et al., 2010); however, in 2018 the AASM downgraded its recommendation regarding the use prazosin (Morgenthaler et al., 2018) based on a single trial (Raskind et al., 2018). We believe that changing the recommendation level for an intervention should be based on the meta-analytic findings of randomized controlled trials (RCTs) which are the highest level of evidence-based methods (Zhang et al., 2020a), rather than the findings of a single trial. Importantly, recent meta-analyses of RCTs have been published, which still support prazosin as an A level treatment for TRN (Yücel et al., 2020; Zhang et al., 2020b).

    • Green synthesis, characterization of procyanidin-mediated gold nanoparticles and its application in fluorescence detection of prazosin

      2022, Microchemical Journal
      Citation Excerpt :

      Based on FRET, OPC-AuNPs acted as an excellent quencher for the commonly used Rhodamine B, realizing a sensitive and accurate fluorescence detection of prazosin. Prazosin, (1 - (4-amino-6,7-dimethoxy-2-quinazolinyl-4 - (2-furyl carbonyl)) piperazine), a kind of α-epinephrine blockers, is widely used for the treatment of hypertension, post-traumatic stress disorder, hyperarousal, nightmares, and Alzheimer's disease, etc. [28–31]. Especially in the treatment of orthostatic hypotension, prazosin exhibits a significant effect [32].

    • A review of the posttraumatic stress disorder and sleep disturbances

      2021, Journal of Sichuan University (Medical Science Edition)
    View full text